KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

被引：653

作者：

de Boer, Ian H. ^{[1
,2
]}

Rossing, Peter ^{[3
,4
,5
,6
]}

Caramori, M. Luiza ^{[7
,8
,9
,10
,11
]}

Chan, Juliana C. N. ^{[12
,13
]}

Heerspink, Hiddo J. L. ^{[14
,15
,16
,17
]}

Hurst, Clint ^{[18
]}

Khunti, Kamlesh ^{[19
,20
,21
,22
,23
,24
,25
]}

Liew, Adrian ^{[26
,27
,28
,29
,30
,31
,32
,33
,34
]}

Michos, Erin D. ^{[35
,36
,37
,38
,39
,40
,41
,42
,43
]}

Navaneethan, Sankar D. ^{[44
,45
,46
,47
]}

Olowu, Wasiu A. ^{[48
,49
]}

Sadusky, Tami ^{[50
,51
,52
,53
,54
,55
]}

Tandon, Nikhil ^{[56
,57
,58
,59
,60
,61
,62
,63
]}

Tuttle, Katherine R. ^{[64
,65
,66
,67
,68
,69
,70
,71
,72
,73
,74
]}

Wanner, Christoph ^{[75
,76
,77
,78
,79
]}

Wilkens, Katy G. ^{[80
,81
,82
]}

Zoungas, Sophia ^{[83
,84
,85
,86
,87
,88
]}

Jadoul, Michel ^{[89
,90
,91
,92
]}

Winkelmayer, Wolfgang C. ^{[92
,93
,94
,95
,96
,97
,98
,99
]}

Tonelli, Marcello A. ^{[100
,101
,102
,103
,104
,105
,106
]}

Craig, Jonathan C. ^{[107
,108
,109
,110
,111
,112
,113
,114
]}

Strippoli, Giovanni F. M. ^{[115
,116
]}

Tunnicliffe, David J. ^{[117
,118
,119
]}

Higgins, Gail Y. ^{[120
,121
,122
,123
]}

Natale, Patrizia ^{[124
,125
,126
]}

Cooper, Tess E. ^{[127
,128
]}

Willis, Narelle S. ^{[129
,130
]}

机构：

[1] Univ Washington, Epidemiol, Seattle, WA 98195 USA

[2] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA

[3] Steno Diabet Ctr Res Team, Copenhagen, Denmark

[4] Univ Copenhagen, Diabet Angiopathy, Copenhagen, Denmark

[5] European Diabet Nephropathy Study Grp, Copenhagen, Denmark

[6] Danish Natl Diabet Registry, Copenhagen, Denmark

[7] Univ Minnesota, Minneapolis, MN USA

[8] Univ Minnesota, Med Ctr, Joint Commiss Accredited Inpatient Diabet Serv, Minneapolis, MN 55455 USA

[9] NIH R01 Grant Study Protect Factors Diabet Kidney, Copenhagen, Denmark

[10] NKF Kidney Dis Outcomes Qual Initiat KDOQI Work G, Copenhagen, Denmark

[11] Diabet Nephropathy Subcomm ADA Sci Sess, Copenhagen, Denmark

[12] Chinese Univ Hong Kong, Med & Therapeut, Hong Kong, Peoples R China

[13] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China

[14] Univ Med Ctr Groningen, Clin Trials & Personalized Med, Groningen, Netherlands

[15] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[16] Univ New South Wales, Sydney, NSW, Australia

[17] George Inst Global Hlth, Sydney, NSW, Australia

[18] US Army, Washington, DC 20310 USA

[19] Univ Leicester, Primary Care Diabet & Vasc Med, Leicester, Leics, England

[20] UK Natl Inst Hlth Res NIHR Appl Res Collaborat AR, Leicester, Leics, England

[21] Ctr Ethn Hlth Res, Leicester, Leics, England

[22] Real World Evidence Unit, Leicester, Leics, England

[23] UK Govt Sci Advisory Grp Emergencies SAGE, Leicester, Leics, England

[24] SAGE Ethn Subpanel, Leicester, Leics, England

[25] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia

[26] Mt Elizabeth Novena Hosp, Kidney & Transplant Practice, Singapore, Singapore

[27] ISPD, Singapore, Singapore

[28] ISN, Execut Comm & Council, Singapore, Singapore

[29] ISN Oceania Southeast Asia Reg Board, Singapore, Singapore

[30] ISN End Stage Kidney Failure Strategy Dialysis Su, Singapore, Singapore

[31] ISN Renal Disaster Preparedness Working Grp, Singapore, Singapore

[32] ISN Dialysis Working Grp, Singapore, Singapore

[33] ISN Continuing Med Educ CME Comm, Singapore, Singapore

[34] Asia Pacific Soc Nephrol APSN CME Comm, Hong Kong, Peoples R China

[35] Johns Hopkins Univ, Div Cardiol, Med, Baltimore, MD USA

[36] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[37] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Womens Cardiovasc Hlth, Baltimore, MD USA

[38] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Prevent Cardiol, Baltimore, MD USA

[39] Board Directors Amer Soc Prevent Cardiol ASPC, Baltimore, MD USA

[40] Amer Coll Cardiol ACC Prevent Leadership Council, Washington, DC USA

[41] ACCs Clin Qual Approval Comm CPAC, Washington, DC USA

[42] AHA Funding Comm, Washington, DC USA

[43] Natl Inst Hlth Funded Multiethn Study Atheroscler, Bethesda, MD USA

[44] Baylor Coll Med, Nephrol Sect, Clin Res, Houston, TX 77030 USA

[45] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA

[46] NKF, New York, NY USA

[47] ASN, New York, NY USA

[48] OAUTHC, Dept Pediat, Pediat Nephrol & Hypertens Unit, Osun, Nigeria

[49] Obafemi Awolowo Univ, Dept Pediat & Child Hlth, Pediat Nephrol, Ife, Nigeria

[50] Univ Washington, Res Finance & Operat, Seattle, WA 98195 USA

来源：

KIDNEY INTERNATIONAL | 2022年 / 102卷 / 05期

关键词：

angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker; chronic kidney disease; dialysis; evidence-based; GLP-1 receptor agonist; glycemia; glycemic monitoring; glycemic targets; guideline; HbAlc; hemodialysis; KDIGO; lifestyle; metformin; models of care; nutrition; renin-angiotensin system; self-management; SGLT2; inhibitor; systematic review; teambased care; CONVERTING-ENZYME-INHIBITION; DIETARY-PROTEIN RESTRICTION; GLUCOSE COTRANSPORTER 2; GLOMERULAR-FILTRATION-RATE; INTENSIFIED MULTIFACTORIAL INTERVENTION; ESTABLISHED CARDIOVASCULAR-DISEASE; INSULIN-DEPENDENT DIABETICS; MODERATE SODIUM RESTRICTION; ASSESSING GLYCEMIC CONTROL; URINARY ALBUMIN EXCRETION;

D O I：

10.1016/j.kint.2022.06.008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained unchanged. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

引用

页码：S1 / S127

页数：127

共 50 条

[1] Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
Navaneethan, Sankar D.
Zoungas, Sophia
Caramori, M. Luiza
Chan, Juliana C. N.
Heerspink, Hiddo J. L.
Hurst, Clint
Liew, Adrian
Michos, Erin D.
Olowu, Wasiu A.
Sadusky, Tami
Tandon, Nikhil
Tuttle, Katherine R.
Wanner, Christoph
Wilkens, Katy G.
Craig, Jonathan C.
Tunnicliffe, David J.
Tonelli, Marcello
Cheung, Michael
Earley, Amy
Rossing, Peter
de Boer, Ian H.
Khunti, Kamlesh
ANNALS OF INTERNAL MEDICINE, 2023, 176 (03) : 381 - 387
[2] Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
Navaneethan, Sankar D.
Zoungas, Sophia
Caramori, M. Luiza
Chan, Juliana C. N.
Heerspink, Hiddo J. L.
Hurst, Clint
Liew, Adrian
Michos, Erin D.
Olowu, Wasiu A.
Sadusky, Tami
Tandon, Nikhil
Tuttle, Katherine R.
Wanner, Christoph
Wilkens, Katy G.
Lytvyn, Lyubov
Craig, Jonathan C.
Tunnicliffe, David J.
Howell, Martin
Tonelli, Marcello
Cheung, Michael
Earley, Amy
Rossing, Peter
de Boer, Ian H.
Khunti, Kamlesh
ANNALS OF INTERNAL MEDICINE, 2021, 174 (03) : 385 - +
[3] Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on New Evidence
Rossing, Peter
Caramori, M. L.
Chan, Juliana C. N.
Heerspink, Hiddo J. L.
Hurst, Clint
Khunti, Kamlesh
Liew, Adrian
Michos, Erin D.
Navaneethan, Sankar D.
Olowu, Wasiu A.
Sadusky, Tami
Tandon, Nikhil
Tuttle, Katherine R.
Wanner, Christoph
Wilkens, Katy G.
Zoungas, Sophia
Craig, Jonathan C.
Tunnicliffe, David J.
Tonelli, Marcello A.
Cheung, Michael
Earley, Amy
de Boer, Ian H.
DIABETOLOGIE UND STOFFWECHSEL, 2025, 20 (01) : 47 - 58
[4] KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Foreword
Kasiske, Bertram L.
Wheeler, David C.
KIDNEY INTERNATIONAL SUPPLEMENTS, 2013, 3 (03) : 260 - 260
[5] KDIGO 2024 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE
Stevens, Paul E.
Ahmed, Sofia B.
Carrero, Juan Jesus
Foster, Bethany
Francis, Anna
Hall, Rasheeda K.
Herrington, Will G.
Hill, Guy
Inker, Lesley A.
Kazancio, Rumeyza
Lamb, Edmund
Lin, Peter
Levin, Adeera
KIDNEY INTERNATIONAL, 2024, 105 (04) : S117 - S117
[6] KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword
Kasiske, Bertram L.
Wheeler, David C.
KIDNEY INTERNATIONAL SUPPLEMENTS, 2013, 3 (01) : 2 - 2
[7] KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
不详
KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (05) : 343 - +
[8] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease Introduction
de Boer, Ian H.
Rossing, Peter
KIDNEY INTERNATIONAL, 2020, 98 (04) : S20 - +
[9] KDIGO Clinical Practice Guideline: Blood Pressure Management for Patients with Chronic Kidney Disease
Robbins, Karen C.
NEPHROLOGY NURSING JOURNAL, 2021, 48 (02) : 183 - 185
[10] Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease
Roberts, Matthew A.
NEPHROLOGY, 2014, 19 (01) : 53 - 55

← 1 2 3 4 5 →